<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02463032</url>
  </required_header>
  <id_info>
    <org_study_id>G200802</org_study_id>
    <nct_id>NCT02463032</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer</brief_title>
  <official_title>A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GTx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GTx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if GTx-024 at different dosages (9 mg or 18 mg) is&#xD;
      effective and safe in the treatment of patients with metastatic or locally advanced Estrogen&#xD;
      Receptor (ER)+ and Androgen Receptor (AR)+ breast cancer in postmenopausal women.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Actual">March 2019</completion_date>
  <primary_completion_date type="Actual">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor (AR)+ Subjects</measure>
    <time_frame>24 weeks</time_frame>
    <description>To estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate, in Full Analysis Set</measure>
    <time_frame>24 weeks</time_frame>
    <description>To estimate the clinical benefit response rate in all subjects randomized who receive at least one dose of study medication (the FAS) regardless of AR status as determined by the central laboratory. o estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response (CR + PR) in AR+ Patients</measure>
    <time_frame>24 weeks</time_frame>
    <description>To estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response in AR+ Patients</measure>
    <time_frame>From treatment initiation to end of treatment</time_frame>
    <description>To estimate the best overall response of GTx-024 9 mg and 18 mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival in All Subjects</measure>
    <time_frame>From randomization to tumor progression or death</time_frame>
    <description>To estimate the progression free survival of subjects receiving Gtx-024 9 mg and 18 mg. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Subjects were assessed up through 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression in All Subjects</measure>
    <time_frame>From randomization to tumor progression or death</time_frame>
    <description>To estimate the time to progression in subjects receiving Gtx-024 9 mg and 18 mg in all subjects. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Time to progression was assessed up through 24 months.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number Subjects Experiencing Adverse Events</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To describe the safety profile of GTx-024 9 mg and 18 mg in all subjects randomized and treated. Reported adverse events were described by system organ class (SOC) as opposed to individual events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>ER+ and AR+ Breast Cancer</condition>
  <arm_group>
    <arm_group_label>GTx-024 9 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GTx-024 18 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GTx-024</intervention_name>
    <description>To determine whether either or both doses result in an acceptable clinical benefit rate.</description>
    <arm_group_label>GTx-024 18 mg</arm_group_label>
    <arm_group_label>GTx-024 9 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult women (≥ 18 years of age) with metastatic or recurrent locally advanced BC, not&#xD;
             amenable to curative treatment by surgery or radiotherapy, with objective evidence of&#xD;
             disease progression.&#xD;
&#xD;
               -  Women must have received ≥ 1 prior hormonal treatment(s) in the metastatic or&#xD;
                  adjuvant setting. If the most recent hormonal treatment was in the metastatic&#xD;
                  setting, duration of response (tumor regression or stabilization of disease) to&#xD;
                  this specific course of therapy must be ≥ 6 months. If the most recent hormonal&#xD;
                  treatment was in the adjuvant setting, duration of response (disease free) to&#xD;
                  this specific course of therapy must be ≥ 3 years&#xD;
&#xD;
          -  Histological or cytological confirmation of ER+ BC as assessed by a local laboratory&#xD;
             using slides, paraffin blocks, or paraffin sample or by medical history: ER+&#xD;
             (confirmed as ER expression more than or equal to 1% positive tumor nuclei)&#xD;
&#xD;
          -  Human epidermal growth factor receptor 2 (HER2)-negative tumor by local laboratory&#xD;
             testing (immunohistochemistry [IHC] 0, 1+ regardless of fluorescence in situ&#xD;
             hybridization [FISH] ratio; IHC 2+ with FISH ratio lower than 2.0 or HER2 gene copy&#xD;
             less than 6.0; FISH ratio of 0, indicating gene deletion, when positive and negative&#xD;
             in situ hybridization [ISH] controls are present)&#xD;
&#xD;
          -  Availability of paraffin embedded or formalin fixed tumor tissue; OR, a minimum of 10&#xD;
             and up to 20 slides of archived tumor tissue or new biopsy, if archived tissue is&#xD;
             unavailable for central laboratory confirmation of AR status and molecular subtyping.&#xD;
             Metastatic tumor tissue is preferred when possible.&#xD;
&#xD;
          -  Postmenopausal women. Postmenopausal status is defined by the National Comprehensive&#xD;
             Cancer Network as either:&#xD;
&#xD;
               -  Age ≥ 55 years and one year or more of amenorrhea&#xD;
&#xD;
               -  Age &lt; 55 years and one year or more of amenorrhea, with an estradiol assay &lt; 20&#xD;
                  pg/mL&#xD;
&#xD;
               -  Age &lt; 55 years and surgical menopause with bilateral oophorectomy a. Note:&#xD;
                  Ovarian radiation or treatment with a luteinizing hormone-releasing hormone&#xD;
                  (LH-RH) agonist (goserelin acetate or leuprolide acetate) is not permitted for&#xD;
                  induction of ovarian suppression at the time of screening. Long term use (&gt;6&#xD;
                  months prior to screening) is permitted&#xD;
&#xD;
          -  Radiological or clinical evidence (bone scan, computerized tomography [CT], and&#xD;
             magnetic resonance Imaging [MRI]) of recurrence or progression within 30 days before&#xD;
             randomization&#xD;
&#xD;
          -  Subject must have either measurable disease or bone only non measurable disease,&#xD;
             according to RECIST1.1&#xD;
&#xD;
          -  Adequate organ function as shown by:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3&#xD;
&#xD;
               -  Platelet count ≥ 100,000 cells/mm3&#xD;
&#xD;
               -  Hemoglobin (Hgb) ≥ 9.0 g/dL&#xD;
&#xD;
               -  Serum aspartate aminotransferase (AST) and alanine transaminase (ALT) ≤ 2.5 upper&#xD;
                  limit of the normal range (ULN) (or ≤ 5 if hepatic metastases are present)&#xD;
&#xD;
               -  Total serum bilirubin ≤ 2.0 × ULN (unless the subject has documented Gilbert&#xD;
                  Syndrome)&#xD;
&#xD;
               -  Alkaline phosphatase levels ≤ 2.5 × ULN (≤ 5 × ULN in subjects with liver&#xD;
                  metastasis)&#xD;
&#xD;
               -  Serum creatinine ≤ 2.0 mg/dL or 177 µmol/L&#xD;
&#xD;
               -  International normalized ratio (INR), activated partial thromboplastin (aPTT), or&#xD;
                  partial thromboplastin time (PTT) &lt; 1.5 × ULN (unless on anticoagulant treatment&#xD;
                  at screening)&#xD;
&#xD;
          -  Subject has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1&#xD;
&#xD;
          -  Subjects with bone metastases should be treated with intravenous bisphosphonates or&#xD;
             subcutaneous denosumab (or investigator preferred standard of care) prior to and/or&#xD;
             during the trial, unless there is a contraindication or subject intolerance to these&#xD;
             therapies. For patients who are normocalcemic, therapy can be initiated at the time&#xD;
             the patient initiates study drug&#xD;
&#xD;
          -  Subject is able to swallow capsules&#xD;
&#xD;
          -  Able and willing to give voluntary, written and signed informed consent before any&#xD;
             screening procedure and according to local guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously received &gt; 1 course of chemotherapy (not including immunotherapies or&#xD;
             targeted therapies) for the treatment of metastatic&#xD;
&#xD;
             a. Note: Subjects may have received 1 course of chemotherapy prior to surgery for the&#xD;
             treatment of locally advanced disease and 1 course of chemotherapy for the treatment&#xD;
             of metastatic BC; however, if surgery could not be performed, this will count as the 1&#xD;
             chemotherapy course allowed prior to study&#xD;
&#xD;
          -  Known hypersensitivity to any of the GTx-024 components or subjects previously&#xD;
             received treatment with SARM&#xD;
&#xD;
          -  Subjects with radiographic evidence of central nervous system (CNS) metastases as&#xD;
             assessed by CT or MRI that are not well controlled (symptomatic or requiring control&#xD;
             with continuous corticosteroid therapy [e.g., dexamethasone])&#xD;
&#xD;
             a. Note: Subjects with CNS metastases are permitted to participate in the study if the&#xD;
             CNS metastases are medically well-controlled and stable for at least 28 days after&#xD;
             receiving local therapy (irradiation, surgery, etc.)&#xD;
&#xD;
          -  Radiotherapy within 14 days prior to randomization except in case of localized&#xD;
             radiotherapy for analgesic purpose or for lytic lesions at risk of fracture, which can&#xD;
             then be completed within 7 days prior to randomization. Subjects must have recovered&#xD;
             from radiotherapy toxicities prior to randomization&#xD;
&#xD;
          -  Currently receiving hormone replacement therapy, unless discontinued prior to&#xD;
             screening&#xD;
&#xD;
          -  Subjects positive for Human Immunodeficiency Virus (HIV)&#xD;
&#xD;
          -  Subject has a concomitant medical condition that precludes adequate study treatment&#xD;
             compliance or assessment, or increases subject risk, in the opinion of the&#xD;
             Investigator, such as but not limited to:&#xD;
&#xD;
               -  Myocardial infarction or arterial thromboembolic events within 6 months prior to&#xD;
                  Baseline or severe or unstable angina, New York Heart Association (NYHA) Class&#xD;
                  III or IV disease, or a QTcB (corrected according to Bazett's formula) interval &gt;&#xD;
                  470 msec&#xD;
&#xD;
               -  Serious uncontrolled cardiac arrhythmia grade II or higher according to NYHA&#xD;
&#xD;
               -  Uncontrolled hypertension (systolic &gt; 150 and/or diastolic &gt; 100 mm Hg)&#xD;
&#xD;
               -  Acute and chronic, active infectious disorders and non malignant medical&#xD;
                  illnesses that are uncontrolled or whose control may be jeopardized by the&#xD;
                  complications of this study therapy&#xD;
&#xD;
               -  Impairment of gastrointestinal function or gastrointestinal disease that may&#xD;
                  significantly alter the absorption of study drugs (e.g., ulcerative disease,&#xD;
                  uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)&#xD;
&#xD;
               -  Another active cancer (excluding adequately treated basal cell carcinoma or&#xD;
                  cervical intraepithelial neoplasia [CIN]/cervical carcinoma in situ or melanoma&#xD;
                  in situ). Prior history of other cancer is allowed as long as there is no active&#xD;
                  disease within the prior 5 years&#xD;
&#xD;
          -  Major surgery within 28 days before randomization&#xD;
&#xD;
          -  Positive hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection at screening&#xD;
&#xD;
          -  History of non-compliance to medical regimens&#xD;
&#xD;
          -  Subjects unwilling to or unable to comply with the protocol&#xD;
&#xD;
          -  Subject is currently receiving treatment with any agent listed on the prohibited&#xD;
             medication list&#xD;
&#xD;
          -  Treatment with any investigational product within &lt; 4 half-lives for each individual&#xD;
             investigational product OR 28 days prior to randomization&#xD;
&#xD;
          -  Current treatment with intravenous bisphosphonate or denosumab with elevated serum&#xD;
             calcium corrected for albumin or ionized calcium levels outside institutional normal&#xD;
             limits at screening&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beth A Overmoyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Susan Smith Center for Women's Cancers, Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Frontier Cancer Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The West Clinic, PC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 2, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <results_first_submitted>September 21, 2020</results_first_submitted>
  <results_first_submitted_qc>December 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 9, 2020</results_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 26, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT02463032/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GTx-024 9 mg</title>
          <description>Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg&#xD;
GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate.</description>
        </group>
        <group group_id="P2">
          <title>GTx-024 18 mg</title>
          <description>Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg&#xD;
GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GTx-024 9 mg</title>
          <description>Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg&#xD;
GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate.</description>
        </group>
        <group group_id="B2">
          <title>GTx-024 18 mg</title>
          <description>Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg&#xD;
GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="64"/>
            <count group_id="B3" value="136"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="35" upper_limit="83"/>
                    <measurement group_id="B2" value="62" lower_limit="33" upper_limit="81"/>
                    <measurement group_id="B3" value="61" lower_limit="33" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Androgen Receptor (AR) status positive</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor (AR)+ Subjects</title>
        <description>To estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GTx-024 9 mg</title>
            <description>Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg&#xD;
GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate.</description>
          </group>
          <group group_id="O2">
            <title>GTx-024 18 mg</title>
            <description>Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg&#xD;
GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor (AR)+ Subjects</title>
          <description>To estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Benefit Rate, in Full Analysis Set</title>
        <description>To estimate the clinical benefit response rate in all subjects randomized who receive at least one dose of study medication (the FAS) regardless of AR status as determined by the central laboratory. o estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GTx-024 9 mg</title>
            <description>Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg&#xD;
GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate.</description>
          </group>
          <group group_id="O2">
            <title>GTx-024 18 mg</title>
            <description>Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg&#xD;
GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Rate, in Full Analysis Set</title>
          <description>To estimate the clinical benefit response rate in all subjects randomized who receive at least one dose of study medication (the FAS) regardless of AR status as determined by the central laboratory. o estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response (CR + PR) in AR+ Patients</title>
        <description>To estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GTx-024 9 mg</title>
            <description>Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg&#xD;
GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate.</description>
          </group>
          <group group_id="O2">
            <title>GTx-024 18 mg</title>
            <description>Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg&#xD;
GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response (CR + PR) in AR+ Patients</title>
          <description>To estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Overall Response in AR+ Patients</title>
        <description>To estimate the best overall response of GTx-024 9 mg and 18 mg</description>
        <time_frame>From treatment initiation to end of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GTx-024 9 mg</title>
            <description>Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg&#xD;
GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate.</description>
          </group>
          <group group_id="O2">
            <title>GTx-024 18 mg</title>
            <description>Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg&#xD;
GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Best Overall Response in AR+ Patients</title>
          <description>To estimate the best overall response of GTx-024 9 mg and 18 mg</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival in All Subjects</title>
        <description>To estimate the progression free survival of subjects receiving Gtx-024 9 mg and 18 mg. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Subjects were assessed up through 24 months.</description>
        <time_frame>From randomization to tumor progression or death</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GTx-024 9 mg</title>
            <description>Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg&#xD;
GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate.</description>
          </group>
          <group group_id="O2">
            <title>GTx-024 18 mg</title>
            <description>Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg&#xD;
GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival in All Subjects</title>
          <description>To estimate the progression free survival of subjects receiving Gtx-024 9 mg and 18 mg. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Subjects were assessed up through 24 months.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="NA" upper_limit="NA">Due to the study ending prematurely and the limited data available, the confidence interval was not reported. This data is NOT available as it was never provided to GTx- the median was the only reported value. All good cause efforts to locate the data have been exhausted, data are missing and hence not available to be reported.</measurement>
                    <measurement group_id="O2" value="2.9" lower_limit="NA" upper_limit="NA">Due to the study ending prematurely and the limited data available, the confidence interval was not reported. This data is NOT available as it was never provided to GTx- the median was the only reported value. Due to the study ending prematurely and the limited data available, the confidence interval was never provided to GTx- the median was the only reported value. All good cause efforts to locate the data have been exhausted, data are missing and hence not available to be reported.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression in All Subjects</title>
        <description>To estimate the time to progression in subjects receiving Gtx-024 9 mg and 18 mg in all subjects. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Time to progression was assessed up through 24 months.</description>
        <time_frame>From randomization to tumor progression or death</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GTx-024 9 mg</title>
            <description>Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg&#xD;
GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate.</description>
          </group>
          <group group_id="O2">
            <title>GTx-024 18 mg</title>
            <description>Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg&#xD;
GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression in All Subjects</title>
          <description>To estimate the time to progression in subjects receiving Gtx-024 9 mg and 18 mg in all subjects. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Time to progression was assessed up through 24 months.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="NA" upper_limit="NA">Due to the study ending prematurely and the limited data available, the confidence interval was not reported. This data is NOT available as it was never provided to GTx- the median was the only reported value. All good cause efforts to locate the data have been exhausted, data are missing and hence not available to be reported.</measurement>
                    <measurement group_id="O2" value="2.9" lower_limit="NA" upper_limit="NA">Due to the study ending prematurely and the limited data available, the confidence interval was not reported. This data is NOT available as it was never provided to GTx- the median was the only reported value. All good cause efforts to locate the data have been exhausted, data are missing and hence not available to be reported.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number Subjects Experiencing Adverse Events</title>
        <description>To describe the safety profile of GTx-024 9 mg and 18 mg in all subjects randomized and treated. Reported adverse events were described by system organ class (SOC) as opposed to individual events</description>
        <time_frame>Up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GTx-024 9 mg</title>
            <description>Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg&#xD;
GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate.</description>
          </group>
          <group group_id="O2">
            <title>GTx-024 18 mg</title>
            <description>Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg&#xD;
GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Number Subjects Experiencing Adverse Events</title>
          <description>To describe the safety profile of GTx-024 9 mg and 18 mg in all subjects randomized and treated. Reported adverse events were described by system organ class (SOC) as opposed to individual events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GTx-024 9 mg</title>
          <description>Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg&#xD;
GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate.</description>
        </group>
        <group group_id="E2">
          <title>GTx-024 18 mg</title>
          <description>Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg&#xD;
GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia and marrow failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>diabetes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>h pylori infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>increased serum creatinine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>increased AST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>tumor flare</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>acute kidney failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI disorder</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>general disorder</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>investigations</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>metabolism</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>nervous system</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mary Breitmeyer</name_or_title>
      <organization>Oncternal</organization>
      <phone>858-434-1113</phone>
      <email>MBreitmeyer@oncternal.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

